Deerfield-based Baxter International is finally giving its turnaround story some numbers to stand on. The medical-device giant reported strong second-quarter results Thursday and raised its full-year outlook, offering investors a clearer sign that its operating reset may be gaining traction.
As reported by Crain's Chicago Business, Baxter's latest performance showed enough improvement for the company to become more confident about the rest of 2026. The higher outlook is the headline, but the more important question is whether the gains can hold after a stretch of uneven execution.
Baxter's turnaround is moving beyond promises
The company entered the year trying to stabilize a sprawling portfolio of infusion products, surgical technologies, pharmaceuticals and connected-care equipment. In April, Baxter reported first-quarter sales of about $2.7 billion, adjusted diluted earnings of 36 cents per share and an organic sales decline of 1%, while reiterating its full-year outlook, according to Baxter's investor release.
That earlier update also laid out the company's repair work: a push to simplify operations, strengthen execution and expand its Baxter Growth and Performance System, an internal improvement program that launched more than 230 initiatives during the first quarter. The new results suggest at least some of that effort is beginning to show up in the business rather than remaining trapped in the corporate slide deck.
A simpler structure is now part of the plan
Just before the second-quarter reporting period, Baxter changed how it organizes and reports the company. In a July filing, the U.S. Securities and Exchange Commission said Baxter would report under two segments, Medical Products & Therapies and Healthcare Systems & Technologies, rather than three, with pharmaceuticals folded into the infusion division.
The change is more than an accounting footnote. Baxter said the structure is intended to better align decision-making, costs and execution across its businesses, a sign that Chief Executive Officer Andrew Hider is trying to make the company easier to run as well as easier to measure.
The Chicago-area medtech giant still has work ahead
Baxter's improved quarter arrives after a rougher finish to 2025. When the company reported fourth-quarter results in February, it said performance had fallen short of expectations and pointed to a new operating model designed to simplify the organization, accelerate innovation and improve consistency, according to Baxter's fourth-quarter release.
So this is progress, not a clean bill of health. For a company whose products are used across hospitals and other care settings worldwide, a stronger quarter and a raised outlook matter—but the real turnaround test will be whether Baxter can keep improving margins, product execution and growth through the back half of the year.
